Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Dicerna Pharmaceuticals (NASDAQ: DRNA)

Organization & Developments: Dicerna

Parents

2017: Dicerna Pharmaceuticals: Buy The Dip - Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)
2018: Our First Look At Dicerna
2018: Our Take On Dicerna Pharmaceuticals_seekingalpha.com
2019: Dicerna And DCR-A1AT In Alpha-1 Antitrypsin Deficiency-Associated Liver Disease_seekingalpha.com
2019: Dicerna Continues To Advance Partnerships For Its Ever Growing Pipeline_seekingalpha.com
2019: Roche signs up Dicerna in a $200M-plus cash alliance to help develop a hep B cocktail, capping biotech’s big year – Endpoints News
2020: Dicerna Pharmaceuticals May Be The Best Value Among RNAi Companies
2020: Dicerna: Great Value RNAi Runner Up
2021: Dicerna A Buy On Long-Term Potential
2021: Dicerna Is A Reasonably Priced Play In The Attractive RNAi Space
2021: Dicerna's RNAi drug shows 'inconsistent' results in rare kidney disease, tanking shares despite trial win
biopharmaceutical company developing novel therapeutic agents in multiple therapeutic areas based on its proprietary Dicer Subst
The company is focused on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases.